211 related articles for article (PubMed ID: 32312965)
1. Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer.
Nallanthighal S; Rada M; Heiserman JP; Cha J; Sage J; Zhou B; Yang W; Hu Y; Korgaonkar C; Hanos CT; Ashkavand Z; Norman K; Orsulic S; Cheon DJ
Cell Death Dis; 2020 Apr; 11(4):258. PubMed ID: 32312965
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
Rada M; Nallanthighal S; Cha J; Ryan K; Sage J; Eldred C; Ullo M; Orsulic S; Cheon DJ
Oncogene; 2018 Aug; 37(35):4809-4820. PubMed ID: 29769618
[TBL] [Abstract][Full Text] [Related]
3. Heat Shock Protein 27, a Novel Downstream Target of Collagen Type XI alpha 1, Synergizes with Fatty Acid Oxidation to Confer Cisplatin Resistance in Ovarian Cancer Cells.
Heiserman JP; Nallanthighal S; Gifford CC; Graham K; Samarakoon R; Gao C; Sage JJ; Zhang W; Higgins PJ; Cheon DJ
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638339
[TBL] [Abstract][Full Text] [Related]
4. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
Wu YH; Huang YF; Chen CC; Chou CY
Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
[TBL] [Abstract][Full Text] [Related]
5. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
[TBL] [Abstract][Full Text] [Related]
6. The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells.
Wu YH; Huang YF; Wu PY; Chang TH; Huang SC; Chou CY
J Ovarian Res; 2023 Jun; 16(1):124. PubMed ID: 37386587
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
8. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
Wu YH; Chang TH; Huang YF; Huang HD; Chou CY
Oncogene; 2014 Jun; 33(26):3432-40. PubMed ID: 23934190
[TBL] [Abstract][Full Text] [Related]
9. Targeting Heat Shock Protein 27 and Fatty Acid Oxidation Augments Cisplatin Treatment in Cisplatin-Resistant Ovarian Cancer Cell Lines.
Heiserman JP; Minhas Z; Nikpayam E; Cheon DJ
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628819
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
11. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression.
Wu YH; Huang YF; Chang TH; Chou CY
Int J Cancer; 2017 Dec; 141(11):2305-2317. PubMed ID: 28815582
[TBL] [Abstract][Full Text] [Related]
12. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
13. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance.
Shen L; Yang M; Lin Q; Zhang Z; Zhu B; Miao C
Oncol Rep; 2016 Aug; 36(2):877-85. PubMed ID: 27373316
[TBL] [Abstract][Full Text] [Related]
14. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
[TBL] [Abstract][Full Text] [Related]
15. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
[TBL] [Abstract][Full Text] [Related]
16. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.
Zhu J; Wu G; Song L; Cao L; Tan Z; Tang M; Li Z; Shi D; Zhang S; Li J
EBioMedicine; 2019 May; 43():238-252. PubMed ID: 31047858
[TBL] [Abstract][Full Text] [Related]
17. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes.
Teng PN; Wang G; Hood BL; Conrads KA; Hamilton CA; Maxwell GL; Darcy KM; Conrads TP
Br J Cancer; 2014 Jan; 110(1):123-32. PubMed ID: 24178762
[TBL] [Abstract][Full Text] [Related]
20. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
